SCHEMBL5017527

SCHEMBL5017527

CCOC(=O)C(OCC)C(O)c1ccc(OCc2ccccc2)cc1OC(C)C

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
EDNRA P25101 1/20 0.43
MAOB P27338 3/20 0.42
PPARG P37231 2/20 0.42
PPARD Q03181 1/20 0.42
PPARA Q07869 1/20 0.42
MEN1 O00255 1/20 0.41
HSP90AA1 P07900 1/20 0.41
KMT2A Q03164 1/20 0.41
NR1H4 Q96RI1 1/20 0.41
ALDH1A1 P00352 1/20 0.41
NMT1 P30419 1/20 0.41
FFAR1 O14842 4/20 0.40
MCL1 Q07820 1/20 0.40
NR4A2 P43354 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3372084 0.92 LMNA (0.51) LMNAL3MBTL1MAOBPPARGPPARD
SCHEMBL5015936 0.86 LMNA (0.52) LMNAL3MBTL1MAOBPPARGPPARD
SCHEMBL5024641 0.83 FFAR1 (0.50) LMNAL3MBTL1MAOBPPARGPPARD
SCHEMBL5024649 0.83 FFAR1 (0.50) LMNAL3MBTL1MAOBPPARGPPARD
SCHEMBL3369824 0.83 FFAR1 (0.50) LMNAL3MBTL1MAOBPPARGPPARD
SCHEMBL3373968 0.80 LMNA (0.47) LMNAL3MBTL1MAOBPPARGPPARD
SCHEMBL3373966 0.80 LMNA (0.47) LMNAL3MBTL1MAOBPPARGPPARD
SCHEMBL3369977 0.80 LMNA (0.47) LMNAL3MBTL1MAOBPPARGPPARD
SCHEMBL5379536 0.79 KMT2A (0.53) LMNAL3MBTL1MAOBMEN1KMT2A
SCHEMBL5358921 0.79 LMNA (0.60) LMNAL3MBTL1MAOBPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551814-B1 CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS HOFFMANN LA ROCHE (CH) 2008-07-23 EP disclosed
US-7348349-B2 Oxazole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-03-25 US disclosed
US-20050267180-A1 Novel oxazole derivatives BINGGELI ALFRED 2005-12-01 US disclosed
US-6969725-B2 Oxazole derivatives HOFFMAN-LA ROCHE INC. (US) 2005-11-29 US disclosed
EP-1551814-A1 CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2005-07-13 EP disclosed
US-20040116487-A1 Novel oxazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-17 US disclosed
WO-2004031162-A1 CHIRALE OXAZOLE-ARYLPROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267180-A1 Novel oxazole derivatives NR1H3, NR1H2, PPARD LMNA 4163/4885L3MBTL1 2945/4885EDNRA 131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.